SupplementaryTable1.xlsx from COVID-19 Infections and Clinical Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic Centers
Introduction: Huntington’s disease (HD) is considered a rare and fatal neurodegenerative disease; despite that, only one study described the outcomes among those with HD and COVID-19. In this context,
Samples collected from myeloma patients at first relapse registered into the Myeloma XII trial, and sent to the following central labs: 1. Central immunology laboratory, University of Birmingham - pe
CR, complete response; ISS, International Staging System; NE, not evaluable; PD, progressive disease; SD, stable disease; VGPR, very good partial response. *Excluded were three patients not evaluable